A naukri.com initiative
The Robot Report
1M
394
Wandercraft raises $75M to scale exoskeletons, humanoids
- Wandercraft raised $75 million in Series D funding to scale its exoskeletons and humanoids.
- The funding will help commercialize the Eve self-balancing personal exoskeleton by 2026.
- Wandercraft aims to expand clinical adoption of its rehabilitation system and deploy its new humanoid, Calvin-40.
- The company's technology is AI-powered through billions of simulations and real-world steps.
- Clinical trials for the personal exoskeleton are underway in New York and will soon begin in New Jersey.
- The exoskeleton benefits individuals with severe mobility impairments by providing walking independence.
- During the 2024 Olympics, Wandercraft's exoskeleton was used to carry the Olympic torch.
- Renault Group, PSIM fund, Bpifrance, Teampact Ventures, and Quadrant Management were major contributors to the funding round.
- Partnership with Renault Group aims to scale production of exoskeletons and industrial robots.
- Renault Group is also Wandercraft's first commercial partner and customer of Calvin-40, an industrial-grade humanoid.
- Calvin-40's rapid development was enabled by Wandercraft's robotics platform integrated with NVIDIA Isaac technologies.
- Wandercraft aims to transform how people live, move, and work across various environments.
- The company has achieved significant momentum through global expansion and pivotal clinical trials.
- Wandercraft continues its mission to enhance rehabilitation and offer innovative robotics solutions.
- The post was originally published on The Robot Report.
Read Full Article
23 Likes
For uninterrupted reading, download the app